IL157898A0 - Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil - Google Patents

Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil

Info

Publication number
IL157898A0
IL157898A0 IL15789802A IL15789802A IL157898A0 IL 157898 A0 IL157898 A0 IL 157898A0 IL 15789802 A IL15789802 A IL 15789802A IL 15789802 A IL15789802 A IL 15789802A IL 157898 A0 IL157898 A0 IL 157898A0
Authority
IL
Israel
Prior art keywords
fluorouracil
gemcitabine
rapamycin
antineoplastic combinations
rapamycin together
Prior art date
Application number
IL15789802A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of IL157898A0 publication Critical patent/IL157898A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15789802A 2001-04-06 2002-04-05 Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil IL157898A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28238801P 2001-04-06 2001-04-06
US28238501P 2001-04-06 2001-04-06
PCT/US2002/010912 WO2002080975A1 (fr) 2001-04-06 2002-04-05 Combinaisons antineoplasiques telles que la rapamycine associee a la gemcitabine ou au fluorouracile

Publications (1)

Publication Number Publication Date
IL157898A0 true IL157898A0 (en) 2004-03-28

Family

ID=26961412

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15789802A IL157898A0 (en) 2001-04-06 2002-04-05 Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil

Country Status (22)

Country Link
EP (1) EP1385551B1 (fr)
JP (1) JP2004525950A (fr)
KR (1) KR100862178B1 (fr)
CN (1) CN1309421C (fr)
AT (1) ATE406892T1 (fr)
AU (1) AU2007242958A1 (fr)
BR (1) BR0208627A (fr)
CA (1) CA2442849A1 (fr)
DE (1) DE60228699D1 (fr)
EA (1) EA010184B1 (fr)
ES (1) ES2312568T3 (fr)
HK (1) HK1060062A1 (fr)
HU (1) HUP0304093A3 (fr)
IL (1) IL157898A0 (fr)
MX (1) MXPA03009092A (fr)
NO (1) NO20034433L (fr)
NZ (1) NZ540047A (fr)
PL (1) PL363991A1 (fr)
PT (1) PT1385551E (fr)
SG (1) SG152906A1 (fr)
SI (1) SI1385551T1 (fr)
WO (1) WO2002080975A1 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1415987B1 (fr) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Composes heteroaromatiques azotes pour le traitement des maladies de cancer
ES2705016T3 (es) 2001-02-19 2019-03-21 Novartis Int Pharmaceutical Ag Derivado de rapamicina para el tratamiento de cáncer de pulmón
GB0124577D0 (en) * 2001-10-12 2001-12-05 Novartis Forschungsstiftung Novel methods
CA2472341C (fr) 2002-02-01 2011-06-21 Ariad Gene Therapeutics, Inc. Composes contenant du phosphore et utilisations associees
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
JP4303726B2 (ja) 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
WO2005082397A1 (fr) * 2004-02-26 2005-09-09 The Penn State Research Foundation Therapie combinatoires pour le traitement des neoplasies a l'aide des recepteurs du facteur de croissance opioide
WO2006027545A2 (fr) * 2004-09-10 2006-03-16 Agency For Science, Technology And Research Procede
JP4834553B2 (ja) 2004-09-17 2011-12-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
CN101155579B (zh) 2005-02-03 2012-10-31 综合医院公司 治疗吉非替尼耐药性癌症的方法
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
EP1962839A4 (fr) * 2005-11-14 2010-08-25 Ariad Pharma Inc Administration d'un inhibiteur de mntor pour le traitement des patients atteints du cancer
GB0523658D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
ES2481671T3 (es) * 2005-11-21 2014-07-31 Novartis Ag Inhibidores de mTOR en el tratamiento de tumores endocrinos
EP1880723A1 (fr) * 2006-07-14 2008-01-23 Novartis AG Combinaison d'un inhibiteur de mTOR et d'un composé anti-folate
AU2007204410A1 (en) * 2006-01-12 2007-07-19 Novartis Ag Combination of mTOR inhibitor and antipolate compound
EP1996193A2 (fr) 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Traitement combiné avec un inhibiteur de kinase egfr et un agent sensibilisant les cellules tumorales aux effets des inhibiteurs de kinase egfr
EP2591775A1 (fr) * 2006-04-05 2013-05-15 Novartis AG Combinaisons comprenant des inhibiteurs de mTOR pour le traitement du cancer
JP5190361B2 (ja) 2006-05-18 2013-04-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 甲状腺癌に対する抗腫瘍剤
JP2009539769A (ja) * 2006-06-02 2009-11-19 アリアド ジーン セラピューティクス インコーポレイテッド カペシタビン併用療法
WO2008016633A2 (fr) * 2006-08-02 2008-02-07 Ariad Gene Therapeutics, Inc. Thérapie par combinaison
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
CA2683109A1 (fr) * 2006-10-11 2008-04-17 Fusion Antibodies Limited Therapie de combinaison
CN103330694A (zh) 2006-11-14 2013-10-02 阿里亚德医药股份有限公司 口服制剂
US20100048503A1 (en) 2007-01-19 2010-02-25 Eisai R & D Management Co., Ltd. Composition for treatment of pancreatic cancer
AU2008211952B2 (en) 2007-01-29 2012-07-19 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
PL2481402T3 (pl) * 2007-03-07 2018-11-30 Abraxis Bioscience, Llc Nanocząstka zawierająca rapamycynę i albuminę jako środek przeciwnowotworowy
JP5579057B2 (ja) 2007-06-01 2014-08-27 アブラクシス バイオサイエンス， エルエルシー 再発性癌の処置のための方法および組成物
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
EP2278966B1 (fr) 2008-03-21 2019-10-09 The University of Chicago Traitement avec des antagonistes des opioïdes et des inhibiteurs mtor
KR20130088908A (ko) 2008-06-17 2013-08-08 와이어쓰 엘엘씨 Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물
CN109464445A (zh) 2008-08-04 2019-03-15 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
ES2941894T3 (es) 2009-04-06 2023-05-26 Wyeth Llc Régimen de tratamiento que utiliza neratinib contra el cáncer de mama
CA2802644C (fr) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Agent anticancereux utilisant des composes ayant un effet inhibiteur de kinase en combinaison
CA2828946C (fr) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Agent therapeutique pour les tumeurs
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
WO2014098176A1 (fr) 2012-12-21 2014-06-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 Forme amorphe de dérivé de quinoline et son procédé de production
KR102204279B1 (ko) 2013-05-14 2021-01-15 에자이 알앤드디 매니지먼트 가부시키가이샤 자궁내막암 대상의 렌바티닙 화합물에 대한 반응성을 예측 및 평가하기 위한 생체표지
MX2017001980A (es) 2014-08-28 2017-05-04 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y metodo para su produccion.
BR112017017428A2 (pt) 2015-02-25 2018-04-03 Eisai R&D Management Co., Ltd. ?método para supressão do amargor de derivado de quinolina?
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
JP6757959B2 (ja) 2015-06-16 2020-09-23 株式会社 ＰＲＩＳＭ ＢｉｏＬａｂ 抗がん剤
PE20190175A1 (es) 2016-03-28 2019-02-01 Incyte Corp Compuestos de pirrolotriazina como inhibidores de tam
AR117600A1 (es) 2018-06-29 2021-08-18 Incyte Corp Formulaciones de un inhibidor de axl / mer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
KR100483256B1 (ko) * 1997-01-24 2005-04-15 콘파마 아에스 젬시타빈 유도체
TW466112B (en) * 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
SI1385551T1 (sl) 2008-12-31
PL363991A1 (en) 2004-11-29
NZ540047A (en) 2007-01-26
PT1385551E (pt) 2008-11-03
EA200301091A1 (ru) 2004-02-26
EP1385551B1 (fr) 2008-09-03
EP1385551A1 (fr) 2004-02-04
CN1309421C (zh) 2007-04-11
CN1545419A (zh) 2004-11-10
HK1060062A1 (en) 2004-07-30
MXPA03009092A (es) 2004-02-12
NO20034433D0 (no) 2003-10-03
HUP0304093A2 (hu) 2004-04-28
BR0208627A (pt) 2004-03-09
KR20040007491A (ko) 2004-01-24
ATE406892T1 (de) 2008-09-15
SG152906A1 (en) 2009-06-29
KR100862178B1 (ko) 2008-10-09
ES2312568T3 (es) 2009-03-01
AU2007242958A1 (en) 2008-01-10
NO20034433L (no) 2003-11-25
CA2442849A1 (fr) 2002-10-17
EA010184B1 (ru) 2008-06-30
JP2004525950A (ja) 2004-08-26
DE60228699D1 (de) 2008-10-16
WO2002080975A1 (fr) 2002-10-17
HUP0304093A3 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
IL157898A0 (en) Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
SG170612A1 (en) Antineoplastic combinations
SG148031A1 (en) Use of cci-779 as an antineoplastic agent
ECSP056001A (es) Combinaciones antineoplásicas
CY2007019I2 (el) Β-αμινο-τετραϋδροϊμιδαζο-(1,2-α)-πυραζινες και τετραϋδροτριαζολο-(4,3-α)-πυραζινες ως αναστολεις της διπεπτιδυλο πεπτιδασης για την αγωγη ή προληψη του διαβητη
TW200420573A (en) Bifunctional heterocyclic compounds and methods of making and using same
AU2003237367A8 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
AU302959S (en) Toothbrush
MXPA05010582A (es) Combinaciones antineoplasicas.
DE60229922D1 (de) Kombinationen, ein antidiarrhoikum und epothilon oder ein epothilonderivat enthaltend
DE60226666D1 (de) Wälz- und Gleitlagerbauteil und Wälzlager
WO2005087265A8 (fr) Combinaisons antineoplastiques de cci-779 et rituximab
SG153647A1 (en) Antineoplastic combinations
ECSP034866A (es) Combinaciones antineoplásticas
ECSP034790A (es) Combinaciones antineoplásticas tales como rapamicin junto con gemcitabina o fluorouracil
AU301530S (en) Air freshening device
AU300158S (en) Underwear